All Blue's $733M bid to ac­quire Zymeworks turns hos­tile as board bat­tles back — af­ter a biotech celebri­ty jumps in

Yes­ter­day, the team at All Blue Cap­i­tal — bent on the takeover of a bad­ly bat­tered Zymeworks — brought in cel­e­brat­ed on­col­o­gist, Pulitzer prize-win­ning writer and biotech ex­ec Sid­dhartha Mukher­jee to add some glitz to their pro­posed board. But they’re still not win­ning over any con­verts.

This morn­ing, Zymeworks’ board of­fi­cial­ly turned this ac­qui­si­tion of­fer in­to a hos­tile show­down, re­ject­ing the un­so­licit­ed of­fer and mar­shal­ing its forces to pre­vent a buy­out at $10.50 per share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER